Sanara MedTech Inc SMTI Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$31.55 down $0.06, 0.19% at close Nov 6
Last close · Previous close $31.61
- Market cap
- $289.12MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$3.72Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$31.55down $3.45, 9.86%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$31.61Nov 5
- Volume44.25KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume121.75KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $16.05 to $35.52; now $31.55
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
SMTI beat the S&P 500 in 3 of 7 periods.
| Period | SMTI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SMTI: down 9.9% S&P 500: down 5.6% | SMTI trailed the S&P 500 by 4.3 percentage points Trailed |
| 3M | SMTI: down 7.5% S&P 500: down 4.1% | SMTI trailed the S&P 500 by 3.4 percentage points Trailed |
| YTD | SMTI: up 35.1% S&P 500: up 8.7% | SMTI beat the S&P 500 by 26.4 percentage points Beat |
| 1Y | SMTI: up 13.2% S&P 500: up 10.9% | SMTI beat the S&P 500 by 2.3 percentage points Beat |
| Long term | ||
| 3Y | SMTI: up 17.9% S&P 500: up 75.0% +5.6% vs +20.5% a year | SMTI trailed the S&P 500 by 57.1 percentage points Trailed |
| 5Y | SMTI: down 16.3% S&P 500: up 67.8% −3.5% vs +10.9% a year | SMTI trailed the S&P 500 by 84.1 percentage points Trailed |
| 10Y | SMTI: up 532.3% S&P 500: up 313.1% +20.3% vs +15.2% a year | SMTI beat the S&P 500 by 219.2 percentage points Beat |
$10,000 invested in SMTI 10 years ago (Nov 4, 2016) would be worth about $63,226 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
SMTI beat the S&P 500 in 3 of 7 periods.
| Period | SMTI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SMTI: down 9.9% S&P 500: down 5.6% | SMTI trailed the S&P 500 by 4.3 percentage points Trailed |
| 3M | SMTI: down 7.5% S&P 500: down 4.3% | SMTI trailed the S&P 500 by 3.2 percentage points Trailed |
| YTD | SMTI: up 35.1% S&P 500: up 7.8% | SMTI beat the S&P 500 by 27.3 percentage points Beat |
| 1Y | SMTI: up 13.2% S&P 500: up 9.7% | SMTI beat the S&P 500 by 3.5 percentage points Beat |
| Long term | ||
| 3Y | SMTI: up 17.9% S&P 500: up 68.8% +5.6% vs +19.1% a year | SMTI trailed the S&P 500 by 50.9 percentage points Trailed |
| 5Y | SMTI: down 16.3% S&P 500: up 56.9% −3.5% vs +9.4% a year | SMTI trailed the S&P 500 by 73.2 percentage points Trailed |
| 10Y | SMTI: up 532.3% S&P 500: up 252.6% +20.3% vs +13.4% a year | SMTI beat the S&P 500 by 279.7 percentage points Beat |
$10,000 invested in SMTI 10 years ago (Nov 4, 2016) would be worth about $63,226 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$79.50
Closing high on . Now 60.3% below that record.
Split-adjusted daily closes since Feb 22, 2011.
Stock splits
1
1-for-100 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$3.72 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 2.6×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 36.4×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 1.56%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $322.23MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own SMTI DCF in Excel. Value Sanara MedTech with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $109.81Mup 13.0%
- Net income
- −$32.01M
- Diluted EPS
- −$3.72
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $21.67M | −$2.86M | −$0.34 |
| Q4 FY24 (Dec 31, 2024) | $26.31M | −$1.54M | −$0.18 |
| Q1 FY25 (Mar 31, 2025) | $23.43M | −$3.53M | −$0.41 |
| Q2 FY25 (Jun 30, 2025) | $25.80M | −$2.01M | −$0.23 |
| Q3 FY25 (Sep 30, 2025) | $26.33M | −$30.41M | −$3.40 |
| Q4 FY25 (Dec 31, 2025) | $27.55M | −$1.61M | −$0.32 |
| Q1 FY26 (Mar 31, 2026) | $27.80M | $458.96K | $0.05 |
| Q2 FY26 (Jun 30, 2026) | $28.14M | −$452.86K | −$0.05 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $24.14M | −$7.92M | −$1.08 |
| FY22 (Dec 31, 2022) | $45.84M | −$7.94M | −$1.00 |
| FY23 (Dec 31, 2023) | $64.99M | −$4.30M | −$0.52 |
| FY24 (Dec 31, 2024) | $86.67M | −$9.66M | −$1.14 |
| FY25 (Dec 31, 2025) | $103.12M | −$37.56M | −$4.36 |
Margins
- Gross 93.0%
- Operating 7.7%
- Net −29.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $4.50MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$5.69MLast 12 months
- Capital spending$1.19MLast 12 months
- 4.1%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $380.02KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$380.02KLast 12 months
8% of free cash flow
Balance sheet
- $29.15MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$48.53MAs of Jun 30, 2026
- Net debt$19.38MAs of Jun 30, 2026
- 2.58As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 6.11As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −473.3%Last 12 months
Over the last 12 months, Sanara MedTech lost money: its net loss was 473.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −45.3%Last 12 months
Over the last 12 months, Sanara MedTech’s net loss was 45.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Sanara MedTech Inc
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX ® Surgical Activated Collagen, FORTIFY TRG ® Tissue Repair Graft and FORTIFY FLOWABLE ® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN ™ Verified Inductive Bone Matrix, ALLOCYTE ® Plus Advanced Viable Bone Matrix, BiFORM ® Bioactive Moldable Matrix, TEXAGEN ® Amniotic Membrane Allograft, and BIASURGE ® Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS ® Antimicrobial Skin and Wound Cleanser, BIAKŌS ® Antimicrobial Wound Gel, and BIAKŌS ® Antimicrobial Skin and Wound Irrigation Solution. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Texas, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
SMTI news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
SMTI stock FAQ
What is SMTI stock’s price today?
Sanara MedTech (SMTI) traded at $31.55 at the close on , down $0.06 (0.19%) from the previous close of $31.61. Over the past 52 weeks it has traded between $16.05 and $35.52.
If you invested $1,000 in SMTI 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in SMTI on would be worth about $6,323 at the close on , a total return of +532.3%. The same $1,000 would be worth $837 if invested five years ago and $1,132 if invested one year ago. Past performance doesn’t predict future returns.
What is Sanara MedTech’s market cap?
Sanara MedTech’s market capitalization is about $289.1 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $31.55 (how market cap works). Sanara MedTech reported 9.16M shares outstanding at the end of its latest quarter ().
What is SMTI’s P/E ratio?
SMTI’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$3.72).
How much revenue does Sanara MedTech make?
Sanara MedTech reported $109.8 million of revenue over the four quarters to , up 13.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $28.1 million, up 9.0% from a year earlier.
Is Sanara MedTech profitable?
Not over the four quarters to . Sanara MedTech reported a net loss of $32.0 million across those four quarters on $109.8 million of revenue. Its operations were still profitable before interest, other items and taxes, with $8.4 million of operating income.
What are SMTI’s earnings per share?
SMTI’s diluted earnings per share were −$3.72 over the four quarters to , compared with −$1.16 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.05 per share, against −$0.23 a year earlier (how EPS works).
Does SMTI pay a dividend?
Sanara MedTech hasn’t paid a dividend in the last twelve months.
What is SMTI’s 52-week high and low?
Over the past 52 weeks SMTI has traded as low as $16.05 and as high as $35.52. At $31.55 at the close on , it is 11.2% below that high and 96.6% above the low.
What is SMTI’s all-time high?
SMTI’s highest closing price was $79.50 on , adjusted for stock splits. At $31.55 at the close on , it is 60.3% below that record.
Has SMTI stock ever split?
Yes, once: 1-for-100 on .
How has SMTI stock performed?
Including dividends and measured to the close on , SMTI has returned +35.1% so far this year and +13.2% over the past year, and −16.3% over five years (−3.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Sanara MedTech in?
Sanara MedTech is in the Healthcare sector and the Medical Instruments & Supplies industry, and is headquartered in Texas, USA.
What exchange does SMTI trade on?
Sanara MedTech trades on the Nasdaq under the ticker symbol SMTI. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.